CONMED (CNMD) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed CONMED (CNMD) over the past year, gaining 52.3% versus a loss of 2.2%. Over five years, CNMD leads with a -68.7% price change compared with -90.4% for PACB. CONMED is the larger company by market cap ($1.33 billion vs $724.2 million), about 1.8 times the size.
CONMED pays a dividend yielding 0.45%, while Pacific Biosciences of California does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNMD | PACB |
|---|---|---|
| Share price | $44.42 | $2.33 |
| Market cap | $1.33B | $724.24M |
| 1-day change | -1.53% | +1.30% |
| YTD return | +9.41% | +24.60% |
| 1-year return | -2.18% | +52.29% |
| 5-year return | -68.72% | -90.45% |
| P/E ratio (TTM) | 24.01 | — |
| Forward P/E | 9.29 | — |
| EPS (TTM) | $1.85 | $-0.43 |
| Dividend yield | 0.45% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $1.37B | — |
| Revenue growth (YoY) | +5.18% | — |
| Net income (latest FY) | $47.05M | — |
| Gross margin | 54.59% | — |
| Operating margin | 7.46% | — |
| Net margin | 3.42% | — |
| 52-week high | $53.66 | $3.44 |
| 52-week low | $31.44 | $1.07 |
| Distance from 52-week high | -17.22% | -32.27% |
| Analyst consensus | none | buy |
| Avg. price target upside | +2.43% | +3.00% |
| Average volume | 482.58K | 10.39M |
| Shares outstanding | 29.95M | 310.83M |
| Employees | 3,900 | 485 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PACB has outperformed CNMD by 54.5 percentage points over the past year.
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Healthcare · Medical Devices · 3,900 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Healthcare · Medical Devices · 485 employees
CNMD vs PACB FAQ
Which is bigger, CONMED or Pacific Biosciences of California?
CONMED (CNMD) is larger, with a market capitalization of $1.33B compared with $724.24M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, CNMD or PACB?
PACB returned +52.29% over the past 12 months, compared with -2.18% for CNMD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, CONMED or Pacific Biosciences of California?
CONMED pays a dividend yielding 0.45%, while Pacific Biosciences of California does not currently pay a regular dividend.
Are CONMED and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.